Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...
Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, ...
The stock's fall snapped a two-day winning streak.
First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...
Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...
Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, today announced a $62 million Series A financing. The financing was led by founding investor Versant Ventures ...
The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...
RyCarma Therapeutics named Adam Rosenberg, former CEO of Aliada Therapeutics and Sionna Therapeutics, as its CEO. It also hired Jonathan Alspaugh as president and chief strategy officer and Sanjay ...
The UK's self-regulated system for disclosing payments from drug companies to healthcare professionals and organizations is ...
Dr. Lubor Gaal joins MitoRx on a part-time basis, bringing over 25 years of global experience in business development, licensing, and strategic partnerships within the pharmaceutical and biotechnology ...
Looking for broad exposure to the Large Cap Blend segment of the US equity market? You should consider the SPDR Russell 1000 Low Volatility Focus ETF (ONEV), a passively managed exchange traded fund ...
When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...